Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis.
Mult Scler
; 24(12): 1605-1616, 2018 10.
Article
em En
| MEDLINE
| ID: mdl-28911260
ABSTRACT
BACKGROUND:
Amiselimod, an oral selective sphingosine-1-phosphate 1 receptor modulator, suppressed disease activity dose-dependently without clinically relevant bradyarrhythmia in a 24-week phase 2, placebo-controlled study in relapsing-remitting multiple sclerosis.OBJECTIVE:
To assess safety and efficacy of amiselimod over 96 weeks.METHODS:
After completing the core study, patients on amiselimod continued at the same dose, whereas those on placebo were randomised 111 to amiselimod 0.1, 0.2 or 0.4 mg for another 72 weeks. Most patients receiving 0.1 mg were re-randomised to 0.2 or 0.4 mg upon availability of the core study results.RESULTS:
Of 415 patients randomised in the core study, 367 (88.4%) entered and 322 (77.6%) completed the extension. One or more adverse events were reported in 303 (82.6%) of 367 patients 'headache', 'lymphocyte count decreased', 'nasopharyngitis' and 'MS relapse' were most common (14.7%-16.9%). No serious opportunistic infection, macular oedema or malignancy was reported and no bradyarrhythmia of clinical concern was observed by Holter or 12-lead electrocardiogram. The dose-dependent effect of amiselimod on clinical and magnetic resonance imaging-related outcomes from the core study was sustained in those continuing on amiselimod and similarly observed after switching to active drug.CONCLUSION:
For up to 2 years of treatment, amiselimod was well tolerated and dose-dependently effective in controlling disease activity.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Propanolaminas
/
Esclerose Múltipla Recidivante-Remitente
Tipo de estudo:
Clinical_trials
Limite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
2018
Tipo de documento:
Article